Management strategies for Barrett's esophagus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 6, 2007, Pages 771-772

  Hillman, Lybus ^a,b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b GastrotrACT   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; EDITORIAL; HUMAN; KOREA; PREVALENCE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 34250327997     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04999.x     Document Type: Editorial

References (15)

1. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med. J. Aust. 2004 180 : 387 91.
2. Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002 122 : 299 307.
3. Chen L, Hu C, Gaboury L et al. Proliferative activity in Barrett's esophagus before and after antireflux surgery. Ann. Surg. 2001 234 : 172 80.
4. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999 117 : 327 35.
5. Falk GW. Barrett's esophagus. Gastroenterology 2002 122 : 1569 91.
6. Peters FTM, Ganesh S, Kuipers EJ et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand. J. Gastroenterol. 2000 12 : 1239 44.
7. Umansky M, Yasui W, Hallak A et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001 20 : 7987 91.
8. Fennerty MB, Triadafilopoulos G. Barrett's related adenocarcinoma: is chemoprevention a potential option? Am. J. Gastroenterol. 2001 96 : 2302 5.
9. Buttar NS, Wang KK, Leontovich O et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002 122 : 1101 12.
10. Fennerty MB. Barrett's-related esophageal cancer: has the final hurdle been cleared, now paving the way for human chemoprevention trials? Gastroenterology 2002 122 : 1172 5.
11. Hillman LC, Chiragakis L, Clarke AC, Kaushik S, Kaye GL. Barrett's esophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma. J. Gastroenterol. Hepatol. 2003 18 : 526 33.
12. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000 119 : 333 8.
13. Spechler SJ. Barrett's esophagus: an overrated cancer risk factor (editorial comment). Gastroenterology 2000 119 : 587 9.
14. Sharma P, McQuaid K, Dent J et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago workshop. Gastroenterology 2004 127 : 310 30.
15. Weinstein M. The prevention and treatment of dysplasia in gastroesophageal reflux disease: the results and challenges ahead. J. Gastroenterol. Hepatol. 2002 17 : S113 S124.